AI-driven high-throughput drug screening on patient-derived tumor organoids

Dr. Christophe Deben (Group Leader, Tumoroid Screening Lab, University of Antwerp and co-founder of Orbits Oncology) presents DrugVision.AI, an AI-powered platform that combines robotic high-throughput screening of patient-derived tumor organoids with live-cell imaging. By integrating Orbits Oncology’s technology, the platform rapidly converts thousands of images into actionable drug response data. Dr. Deben shares a case study revealing a novel compound that boosts the effectiveness of current therapies, showcasing the potential of AI to advance precision oncology.